NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
34 trialsNCT01560416 2026-03-03
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03783949 2025-06-11
EUDARIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT01962948 2024-03-26
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT01167114 2023-11-02
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT01579994 2020-12-30
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01590160 2019-11-13
MESO-02
University College, London
Phase 1/2 Completed
NCT02012192 2019-08-13
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
Medical University Innsbruck
Phase 1/2 Terminated
NCT02389751 2019-07-24
Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02008877 2019-05-15
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Sarcoma Alliance for Research through Collaboration
Phase 1/2 Completed
NCT01173523 2019-04-16
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01200238 2018-10-18
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01270880 2018-09-18
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT02060253 2018-06-14
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01665937 2018-04-25
STA-9090 in Patients With Advanced Hepatocellular Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT02261805 2018-04-23
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
Georgetown University
Phase 1/2 Terminated
NCT02192541 2018-03-29
Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01551693 2017-04-12
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02334319 2016-07-26
Ganetespib Window of Opportunity Study in Head and Neck Cancers
Emory University
Phase 1 Terminated
NCT01798485 2016-07-01
Galaxy 2
Synta Pharmaceuticals Corp.
Phase 3 Terminated
NCT02637375 2016-05-30
A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer
University of Chicago
Phase NA Withdrawn
NCT01554969 2016-02-22
Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
Emory University
Phase 1 Completed
NCT01111838 2015-11-20
Clinical and Translational Study of STA-9090
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01273896 2015-11-20
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01677455 2015-11-05
Enchant
Synta Pharmaceuticals Corp.
Phase 2 Completed
NCT01485835 2015-10-12
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Emory University
Phase 1 Completed
NCT01368003 2015-09-01
STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT01031225 2014-09-19
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
Synta Pharmaceuticals Corp.
Phase 2 Completed
NCT01183364 2014-09-19
A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT00687934 2014-09-18
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT00688116 2014-09-18
Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Unknown
NCT00858572 2014-09-18
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT00964873 2014-09-18
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT01227018 2014-07-23
PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated